Open AccessElevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus (SLE)
Author(s) -
Mitsuhiro Kawano,
Tsukasa Seya,
Ichiro Koni,
Hiroshi Mabuchi
Publication year - 1999
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1046/j.1365-2249.1999.00917.x
Subject(s) - cd46 , immunology , complement system , rheumatoid arthritis , complement factor i , medicine , haptoglobin , arthritis , antibody , endocrinology
Membrane cofactor protein (MCP, CD46) is a cell surface complement regulatory protein which acts as a cofactor for the factor I‐mediated cleavage of the activated complement components C3b/C4b. To evaluate the clinical usefulness of serum soluble CD46 as a marker of disease activity in patients with SLE, serum levels of sCD46 were measured by ELISA, using two MoAbs (M160 and M177), each of which recognized two different epitopes on CD46 molecule in SLE, other autoimmune diseases and healthy controls. Serum sCD46 levels in active SLE patients (30.5 ± 14.1 ng/ml) were significantly higher than those of inactive SLE (5.8 ± 7.1 ng/ml; P = 0.0003), rheumatoid arthritis (14.9 ± 11.6 ng/ml; P = 0.0218), primary Sjögren's syndrome (12.3 ± 11.6 ng/ml; P = 0.0039) and normal controls (7.3 ± 3.6 ng/ml; P = 0.0005). The elevated serum sCD46 levels in active SLE patients significantly decreased from 30.5 ± 14.1 ng/ml to 8.0 ± 6.3 ng/ml after effective corticosteroid and immunosuppressant therapy ( P = 0.018). Additionally, we found a significant negative association between increasing concentration of sCD46 and decreasing levels of CH50 in SLE ( r = –0.598, P = 0.0009). These results suggest that sCD46 reflects in vivo activation of complement system and provides an additional useful serum parameter of active SLE.